Products
NUTRACEUTICAL – COLON CANCER
Forchronic has developed a validated nutritional supplement in the context of precision nutrition, formulated from rosemary extract, with supercritical extraction, which has immunomodulatory and anti-inflammatory activity, and which inhibits the synthesis of DNA and lipid metabolism at the molecular level and, consequently, inhibits cell proliferation as well as the migration of tumor cells (metastasis) in colon cancer.
The formulation strategy for bioactive carrier lipids is exclusive of Forchronic, which bases it on the development of new precision nutrition products and specific use for health.
Current phase: in clinical trials.
Development of the Bioactive Suplement
Preclinical Phase
Clinical Trials
Lab studies
Assays in animals
Clinical trial in healthy volunteers
Pilot study in phase 0/I
Clinical trial in phase II/III
Identification of the compound
Development of
the compound
Inhibition of molecular pathways associated with tumor growth
Potentiation of chemotherapy (fluoropyridines)
Made in 60
healthy volunteers
Absence of toxicity and potentiation of the immune system
Made in 11 patients
for 2 weeks
Verification of tolerability, absence of toxicity and enhancement of the immune system
Multicenter trial in 150 colon cancer patients receiving chemotherapy (5-Fu)
Under review by the
Clinical Research Ethics
Committee
In the current phase of clinical trials in patients with colorectal cancer the first positive results have already been obtained.
The preventive, antitumor and immune potentiating properties shown in the trial in healthy volunteers have also been observed in sick patients.
La fórmula de este compuesto contiene un portador lipídico de elevada bioactividad, que permite abordar estrategias terapéuticas para el cáncer mediante productos similares en el ámbito alimentario y por tanto, considerados complementos nutricionales y no fármacos. Este carrier lipídico aumenta la biodisponibilidad de los principios activos, mejorando la estabilidad del producto durante la digestión y la bioaccesibilidad del mismo.
La estrategia de formulación sobre lípidos portadores bioactivos es exclusiva de Forchronic que basa en ella el desarrollo de nuevos productos de nutrición de precisión y de uso específicos para la salud.
Current status
in clinical trials
Development in Bioactive Suplement
Lab studies
Identification of the compound
Development of
the compound
Preclinical Phase
Assays in animals
Inhibition of molecular pathways associated with tumor growth
Potentiation of chemotherapy (fluoropyridines)
Clinical Trials
Clinical trial in healthy volunteers
Made in 60
healthy volunteers
Absence of toxicity and potentiation of the immune system
Pilot study in phase 0/I
Made in
11 patients
for 2 weeks
Verification of tolerability, absence of toxicity and enhancement of the immune system
Clinical trial in phase II/III
Multicenter trial in 150 colon cancer patients receiving chemotherapy (5-Fu)
Under review by the Clinica
l Research Ethics Committee
Investigación Clínica
In the current phase of clinical trials in patients with colorectal cancer the first positive results have already been obtained.
The preventive, antitumor and immune potentiating properties shown in the trial in healthy volunteers have also been observed in sick patients.
NUTRACEUTICAL – BREAST CANCER
Development of the nutritional supplement based on rosemary extract with therapeutic activity in breast cancer.
Current phase: start phase II / III of clinical trials in 100 patients with breast cancer at the beginning of 2020.
Development in Bioactive Suplement
In vitro assays / preclinical phase
Clinical Trial with Healthy volunteers
Clinical Trial in Patients
NUTRACEUTICAL – OTHER TUMORS
Applicability of the nutraceutical product based on rosemary extract and carried in the lipid vehicle of high bioactivity in other types of tumors, such as lung cancer.
Current phase: start phase II / III of clinical trials in 50 patients with lung cancer at the beginning of 2020.
NUTRACEUTICAL – AUTOIMMUNE DISEASES:
Current phase: clinical trials in healthy volunteers.
NEWS NUTRACEUTICAL PRODUCTS
Extracts of yarrow and calendula for pancreatic cancer, obesity, metabolic syndrome and metabolic diseases.
Current phase: preclinical phase. Forecast to clinical trial in human volunteers for extract of yarrow.
Phone
(+34) 91 104 46 75
(+34) 91 104 46 76
Address
Ground floor, office D
28108, Alcobendas, MADRID
Office Hours
8:15 – 16:45
